Business Context and Reporting Period
This Form 8-K is a current report filed by WellPoint, Inc. (now Elevance Health, Inc.) on September 14, 2012, covering events occurring on September 11 and September 12, 2012. The filing addresses corporate governance changes, specifically executive compensation adjustments and amendments to the Company's By-Laws.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation:
- Interim CEO Base Salary: Increased to $83,333 per month for John Cannon.
- Target Annual Cash Incentive: Set at 110% of base salary.
- Restricted Stock Units (RSUs): Grant valued at $2.5 million.
Material Changes
The following material changes were reported:
- Executive Compensation: On September 11, 2012, the Compensation Committee approved changes to John Cannon's compensation in connection with his appointment as Interim President and CEO. The base salary increase and cash incentive target are effective as of August 27, 2012. A grant of $2.5 million in RSUs was approved with a grant date of October 1, 2012, vesting in four equal annual installments starting October 1, 2013.
- By-Law Amendments: On September 12, 2012, the Board adopted amendments to Article III of the By-Laws. These changes allow the CEO to be, but are not required to be, a Board member. Additionally, the CEO is authorized to preside over Board meetings in the absence of the Chair and Lead Director, provided the CEO is a Director at that time.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies are disclosed in this report other than the standard terms and conditions applicable to the restricted stock unit award agreement.
Investor Verification Checklist
- Verify the vesting schedule and performance conditions attached to the $2.5 million RSU grant to John Cannon.
- Confirm the effective date of the By-Law amendments regarding CEO Board membership and meeting presiding rights.
- Review the full text of the amended By-Laws (Exhibit 3.2) and the RSU Award Agreement (Exhibit 10.2(t)) filed with this report.